ACET Short Information, Aceto Corporation

Twenty Trading Day Totals
Total Shorted Volume	2,873,872
Total Actual Volume	18,330,407

Averages
Average Short Volume	143,694
Average Short Percentage	46.58%

Is there a ACET Short Squeeze or Breakout about to happen?

See the ACET Short Analysis for free Sign up or Login

Stock Date	Open Price	Close Price	High	Low	Total Volume	Short Volume	Short Percentage
2022-06-30	14.19	14.6	14.71	14.08	517,749	29,822	44.7711
2022-06-29	13.87	14.58	14.65	13.519	312,380	25,019	53.9517
2022-06-28	14.4	14	14.57	13.78	434,296	67,990	63.5694
2022-06-27	13.85	14.36	14.42	13.48	416,703	37,640	24.1032
2022-06-24	12.27	13.63	13.69	12.11	794,213	79,585	55.2045
2022-06-23	11.89	12.02	12.04	11.41	475,062	20,661	11.7271
2022-06-22	11.88	11.87	12.34	11.65	756,065	41,056	15.0001
2022-06-21	11.89	12	12.36	11.77	577,920	46,396	27.8799
2022-06-16	11	10.83	11.18	10.73	802,028	148,211	45.6243
2022-06-15	11.36	11.36	11.7	11.02	530,463	83,363	44.6862
2022-06-14	11.45	11.29	11.61	11.01	1,145,398	171,136	39.0826
2022-06-13	11.38	11.35	11.55	11.14	792,086	157,496	65.3519
2022-06-09	12.74	12.49	12.84	12.34	808,156	119,749	34.4035
2022-06-08	13.04	12.8	13.49	12.725	1,122,059	92,826	43.9045
2022-06-06	11.77	12.26	12.92	11.1	3,282,278	443,004	34.2855
2022-06-03	11.35	11.5	12.15	11.24	574,820	69,998	63.8627
2022-06-02	11.17	11.49	11.85	11.0599	449,173	61,601	52.2175
2022-06-01	11.86	11.29	12.5	11.28	998,224	221,858	77.6898
2022-05-31	11.62	11.82	11.91	10.99	1,098,544	93,573	58.8713
2022-05-27	11.11	11.75	11.75	10.77	2,442,790	862,888	75.3454

Stock Information

Aceto Corporation Company Name:

ACET Stock Symbol:

NASDAQ Market:

Aceto Corporation Website:

Get ACET Alerts

News, Short Squeeze, Breakout and More Instantly...

ACET - Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive Non-Hodgkin’s Lymphoma (NHL) , a s of May 31, 2022 data-cut date 80% ORR and CR rate at dose...
ACET - Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)

As of the February 14, 2022 ASCO abstract data-cut date, ADI-001 demonstrated a 67% complete response rate with positive preliminary durability data and a favorable safety and tolerability profile Updated data from a May 31, 2022 data-cut date will be presented during oral presentat...
ACET - Adicet Bio to Present at Upcoming Investor Conferences

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor confere...